Start Here How HIV and kidney health interact
The short version: The kidneys quietly filter your blood 24 hours a day, and HIV plus certain HIV medications (especially tenofovir disoproxil fumarate, or TDF) can put them under stress. Chronic kidney disease is more common in people living with HIV than in the general population, but with routine monitoring (creatinine, eGFR, urine protein) and the right ART choice most kidney problems are caught early or avoided entirely. What follows is what to watch for, which labs matter, and when to talk to your provider about switching regimens.
← All Deep DivesWhy People Living with HIV Have Higher Kidney Disease Risk
Chronic kidney disease (CKD) is significantly more common in people living with HIV than in the general population. Studies consistently show that people living with HIV have two to four times the risk of developing CKD compared to HIV-negative individuals of similar age and background[1]. This elevated risk comes from multiple sources — and understanding them is the first step toward protecting kidney function long-term.
The multiple drivers of kidney risk in people living with HIV
- HIV itself: The virus directly infects kidney cells and causes chronic inflammation that damages kidney tissue. Even with viral suppression, residual immune activation can continue to affect kidney function.
- Antiretroviral medications: Certain ART medications — particularly tenofovir disoproxil fumarate (TDF) — are associated with kidney tubular toxicity and reduced glomerular filtration rate in some patients, especially those with pre-existing risk factors.
- Hypertension: High blood pressure is both more common in people living with HIV and one of the leading causes of CKD. HIV-associated inflammation contributes to hypertension, and certain ART regimens can affect blood pressure.
- Diabetes: Diabetic nephropathy is the leading cause of CKD in the general population — and people living with HIV have elevated diabetes risk from both HIV itself and some ART medications' metabolic effects.
- Hepatitis C coinfection: HCV independently damages the kidneys through immune complex deposition. Anyone living with HIV who also has untreated HCV faces compounded kidney risk.
- Race: Black people living with HIV face particularly elevated CKD risk — partly due to the APOL1 gene variants more common in people of West African ancestry, which dramatically increase susceptibility to HIV-associated nephropathy (HIVAN).
- Aging: Normal aging reduces kidney function. When HIV-related and medication-related kidney stress compounds normal aging, the cumulative effect can accelerate decline significantly.
Kidney disease is called a silent disease because it rarely causes symptoms until significant damage has occurred. For people living with HIV — who face elevated risk from multiple directions — regular monitoring is not optional. It is how you catch the problem before it becomes irreversible.
HIV-Associated Nephropathy (HIVAN)
HIV-Associated Nephropathy — HIVAN — is a specific form of kidney disease caused directly by HIV infection of kidney cells[2]. It is the most severe and most rapidly progressive kidney disease seen in people living with HIV, and without treatment it can progress to end-stage renal disease within months.
HIVAN has a striking racial disparity: it occurs almost exclusively in Black patients, and the risk is strongly associated with two APOL1 gene variants (G1 and G2) more common in people of West African ancestry[3]. It was one of the most devastating complications of advanced HIV disease in the pre-treatment era — and today, with effective ART, it is far less common. But it has not disappeared, and it remains a significant risk for Black people living with HIV who are not in care or not virally suppressed[4].
HIVAN — Key Facts
- Who is at risk: Primarily Black people living with HIV, particularly those with high viral loads or advanced HIV disease. Rarely occurs in virally suppressed patients.
- How it presents: Large amounts of protein in the urine (proteinuria), rapidly declining kidney function, swelling — often developing quickly over weeks to months
- Treatment: Effective ART is the primary treatment — suppressing HIV dramatically slows or halts HIVAN progression. In some cases, ACE inhibitors or ARBs are added to reduce proteinuria and protect kidney function
- Prognosis with treatment: Excellent if caught early and treated aggressively. Without ART, prognosis is poor. This is one of the strongest arguments for early HIV treatment — before kidney damage occurs.
ART Medications and the Kidneys
The relationship between antiretroviral therapy and kidney health is nuanced. ART is essential and the benefits dramatically outweigh the risks for the vast majority of people living with HIV. But certain medications have specific kidney effects that warrant monitoring — particularly in people with pre-existing risk factors. The DHHS HIV Clinical Guidelines lay out the current evidence and monitoring recommendations for each regimen[5].
ART Medications and Kidney Effects
- Tenofovir disoproxil fumarate (TDF) — in Truvada, Atripla, Cimduo, others: The most clinically significant kidney concern in modern ART. TDF is associated with proximal tubular toxicity — damage to the kidney tubules that handle filtration[6]. In most people on TDF, the effect is mild and stable. In people with pre-existing CKD, diabetes, hypertension, or low body weight, the risk is higher — and toxicity is exacerbated when TDF is combined with pharmacologic boosters like ritonavir or cobicistat[7]. Creatinine and urinalysis should be monitored regularly on TDF-containing regimens.
- Tenofovir alafenamide (TAF) — in Descovy, Biktarvy, Odefsey, others: A newer formulation of tenofovir that achieves equivalent antiviral effect at much lower plasma concentrations — significantly reducing kidney and bone toxicity[8]. For people with kidney risk factors, switching from TDF to TAF-based regimens is often considered. TAF-containing regimens are approved for people with eGFR ≥ 30 mL/min. Discuss with your HIV provider.
- Atazanavir (Reyataz): Associated with kidney stone formation (nephrolithiasis) in some people — particularly those who are dehydrated or have other stone risk factors. Adequate hydration is important on atazanavir.
- Indinavir: An older protease inhibitor now rarely used — strongly associated with kidney stones and chronic kidney damage. Long-term survivors who took indinavir may have residual kidney effects.
- Creatinine elevation from cobicistat/ritonavir boosting: Cobicistat and ritonavir — used as pharmacokinetic boosters in many regimens — can raise creatinine levels by blocking its secretion in the kidney tubules. This looks like reduced kidney function on labs but is not true GFR decline. Your provider should be aware of this artifact when interpreting your creatinine on a boosted regimen.
What to Monitor — Your Kidney Labs Explained
Kidney function monitoring is a standard part of HIV care — it should be happening at every routine lab draw. Knowing what the tests measure and what the numbers mean helps you participate in your own care. See the National Kidney Foundation's HIV and kidney disease overview for a plain-language guide[9].
| Lab Test | What It Measures | What to Know |
|---|---|---|
| Serum Creatinine | A waste product filtered by the kidneys — elevated levels suggest reduced filtration | Normal range varies by age, sex, and muscle mass. A trend upward over time is more meaningful than a single value. Can be artificially elevated by cobicistat/ritonavir boosting. |
| eGFR (estimated Glomerular Filtration Rate) | Calculated estimate of how much blood the kidneys filter per minute — the primary measure of kidney function | Normal is above 60 mL/min/1.73m². Below 60 = CKD. Below 15 = kidney failure. eGFR naturally declines with age — what matters is the rate of decline and whether it exceeds normal aging. |
| Urinalysis (with microscopy) | Screens urine for protein, blood, glucose, and other markers of kidney or urinary tract disease | Protein in the urine (proteinuria) is one of the earliest signs of kidney damage — including HIVAN. Should be checked at least annually for people living with HIV. |
| Urine Protein-to-Creatinine Ratio (UPCR) | Quantifies how much protein is leaking into the urine — a more precise measure than qualitative urinalysis | Used to monitor patients with known proteinuria or high CKD risk. Significant proteinuria warrants nephrology referral. |
| Urine Phosphate / Tubular Markers | Measures of tubular function — relevant specifically for monitoring TDF toxicity | Tubular dysfunction from TDF can appear before eGFR declines. If you're on TDF and have risk factors, ask whether tubular markers are being checked. |
| Blood Pressure | Not a kidney lab per se — but hypertension is both a cause and a consequence of CKD | Target blood pressure in CKD is generally below 130/80. Know your numbers at every visit. |
Symptoms of Kidney Disease — Don't Wait for Them
Early and moderate kidney disease typically causes no symptoms. By the time symptoms appear — swelling in the legs and ankles, fatigue, decreased urine output, nausea, confusion — significant damage has usually already occurred. This is why regular lab monitoring matters. Don't wait to feel sick to ask about your kidney numbers.
Protecting Your Kidneys — What You Can Control
Evidence-based kidney protection strategies
- Stay virally suppressed: The most important kidney protection is controlling HIV itself. HIVAN doesn't occur in virally suppressed patients, and chronic HIV-driven inflammation is reduced with viral suppression[4]. Staying undetectable also means Undetectable = Untransmittable (U=U)[10] — the same viral suppression that protects your kidneys is what makes HIV sexually untransmittable. ART is kidney-protective when it replaces uncontrolled viral replication.
- Control blood pressure: Target below 130/80. If blood pressure medication is needed, ACE inhibitors and ARBs are preferred for people living with HIV who have CKD because they also reduce proteinuria. Discuss with your provider.
- Manage diabetes: If you have diabetes, tight glycemic control slows CKD progression. SGLT2 inhibitors — a class of diabetes medication — have specific evidence for kidney protection in diabetic CKD and are increasingly used in people living with HIV.
- Stay hydrated: Adequate fluid intake supports kidney filtration and reduces kidney stone risk, particularly relevant for people on atazanavir or with a history of stones.
- Avoid nephrotoxic medications: NSAIDs (ibuprofen, naproxen) reduce blood flow to the kidneys and can cause acute kidney injury — particularly in people with pre-existing CKD or dehydration. Use with caution and discuss with your provider. IV contrast dye (used in some CT scans) can also be nephrotoxic — always tell your provider about any kidney issues before imaging with contrast.
- Treat HCV if coinfected: Curing HCV with direct-acting antivirals removes a significant independent driver of kidney damage.
- Discuss TDF vs TAF with your provider: If you have kidney risk factors and are on a TDF-containing regimen, ask whether a TAF-based alternative is appropriate for you.
If CKD Is Diagnosed — What Comes Next
A diagnosis of chronic kidney disease is not a crisis — it is information. Many people with CKD stages 1–3 (eGFR above 30) live well for decades without progression to kidney failure, particularly with good management of the contributing factors. What matters is catching it, understanding it, and managing it systematically.
CKD management for people living with HIV
- Nephrology referral: Most HIV providers will refer to nephrology when eGFR falls below 60 or when proteinuria is significant. A nephrologist who has experience with HIV is ideal — major HIV centers typically have this collaboration established.
- ART regimen review: CKD diagnosis should trigger a review of your ART regimen with your HIV provider. TDF-containing regimens may need to be switched. Dose adjustments may be needed for certain medications as kidney function declines.
- Dietary modifications: In more advanced CKD (stages 3–5), dietary modifications — reduced potassium, phosphorus, and sometimes protein — become important. A renal dietitian can help navigate this without compromising nutrition.
- Anemia management: CKD reduces erythropoietin production, leading to anemia — which can compound HIV-related fatigue. This is treatable and should be monitored.
- Kidney transplant: For people living with HIV who progress to end-stage renal disease, kidney transplant is now an established option. Outcomes for transplant recipients living with HIV have improved dramatically, and transplantation is no longer withheld on the basis of HIV status alone[11]. Under the HOPE Act, HIV-to-HIV kidney transplantation is permitted — and following 2024 federal regulatory changes and June 2025 OPTN policy updates, HIV-to-HIV kidney transplants are no longer restricted to research protocols[12].
Florida — Kidney Care for People Living with HIV
🌴 Florida Resources for Kidney Health
University of Miami — HIV and Nephrology: The University of Miami has integrated HIV and nephrology expertise, with specific experience in HIVAN and CKD care for people living with HIV. For complex kidney disease in South Florida, UM is the primary academic referral center.
University of Florida Health (Gainesville): UF Health's nephrology program has experience managing kidney disease in people living with HIV. For patients in North and Central Florida, UF Health or Jacksonville's UF Health campus are key referral destinations.
Ryan White kidney care coverage: Nephrology visits and kidney-related lab monitoring are covered services under the Ryan White HIV/AIDS Program for eligible people living with HIV[13]. Ask your Ryan White case manager whether nephrology referral and specialist visits are covered in your program.
Florida Kidney Foundation: Provides patient education, support groups, and financial assistance for patients with kidney disease in Florida. floridakidney.org →
Dialysis access: If you have reached end-stage renal disease and require dialysis, federally funded dialysis centers cannot discriminate on the basis of HIV status. All dialysis centers must follow standard infection control protocols that are safe for people living with HIV.
Use the RiseUpToHIV Florida Locator to find HIV specialty care near you — and ask your HIV provider about nephrology coordination.
References & Sources
- Mocroft A et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients (D:A:D study). AIDS (2010) — established the 2–4× elevated CKD prevalence in PLHIV vs. matched general population. PubMed ↩
- Wearne N et al. HIV-associated nephropathy: pathogenesis, clinical presentation, and treatment. (Review) — HIVAN as direct viral infection of kidney cells with rapid progression. PMC ↩
- Kopp JB et al. APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black Patients. Journal of the American Society of Nephrology. PMC · NIH: gene variant news release ↩
- Foy MC et al. Progression of HIV-1 CKDs: Viral Load Versus APOL1 Risk. Kidney International Reports. Viral suppression halts HIVAN progression; unsuppressed disease is the highest-risk state. PMC ↩
- U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Clinicalinfo.HIV.gov. clinicalinfo.hiv.gov ↩
- Fernandez-Fernandez B et al. Tenofovir Nephrotoxicity: 2011 Update. AIDS Research and Treatment — mechanism of TDF proximal tubular toxicity. PMC ↩
- Ryom L et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. Journal of Infectious Diseases. Boosted TDF regimens carry higher renal risk than unboosted. PubMed ↩
- Sax PE et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate: renal and bone safety. Clinical trial data showed lower plasma tenofovir and reduced renal/bone biomarker changes with TAF. Summarized in DHHS ARV Guidelines (see fn 5). PubMed ↩
- National Kidney Foundation. HIV and Kidney Disease. Plain-language patient guide. kidney.org ↩
- Centers for Disease Control and Prevention. HIV Treatment as Prevention (U=U). cdc.gov ↩
- Durand CM et al. Safety of Kidney Transplantation from Donors with HIV. New England Journal of Medicine — outcomes for HIV-to-HIV kidney transplants comparable to HIV-negative donor sources. PMC ↩
- OPTN / HRSA. HOPE Act Policy Update, effective June 26, 2025 — removes research-protocol requirement for HIV-to-HIV liver and kidney transplants. hrsa.gov (PDF) · HIV.gov background: HIV.gov ↩
- Health Resources and Services Administration. Ryan White HIV/AIDS Program — Core Medical Services and Specialty Care. ryanwhite.hrsa.gov ↩